For the period, Philips' Diagnosis & Treatment unit had sales of 2.154 billion euros ($2.501 billion U.S.), compared with 1.971 billion euros ($2.289 billion U.S.), in the third quarter of 2020. Sales growth was 9% on a nominal basis and 10% after adjustment for currency effects.
The company said it saw double-digit growth in its image-guided therapy and enterprise diagnostic informatics segments, with growth in the high single digits in its ultrasound and diagnostic imaging businesses. Order intake increased by 15%, compared with a 3% decline for the same period last year.
On a profit basis, the Diagnosis & Treatment businesses had income from operations of 271 million euros ($314.8 million), up from 2020's 99 million euros ($115.5 million). Adjusted earnings before interest, taxes, and amortization (EBITA) margin as a percent of sales increased from 9.7% to 14.2%, the company said.
In its financial report, the company highlighted the release of its new Spectral CT 7500 system, and a contract with the Yili Chuanxin Oncology hospital in Xinjiang for its IntelliSpace Digital Pathology and the Ingenia 3.0T MR, IQon Spectral CT, Incisive CT, and CT Big Bore imaging systems.
Copyright © 2021 AuntMinnie.com